Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial
Joseph A. Murray, Dina Wassaf, Karen Dunn, Samir Arora, Peter Winkle, Helen Stacey, Simon Cooper, Kaela E. Goldstein, Rajesh V. Manchanda, Stephan Kontos, Kristie M. Grebe
Topics & Concepts
MedicineTolerabilityDosingInternal medicineCoeliac diseasePlaceboGastroenterologyClinical endpointAdverse effectClinical trialSurgeryDiseasePathologyAlternative medicineCeliac Disease Research and ManagementMicroscopic ColitisGastrointestinal motility and disorders